Clinical Trial Update: Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of Ingenol Mebutate Gel 0.06% applied once daily for 2, 3, or 4 consecutive days to a ~250 cm2 area on the trun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Ingenol Mebutate Gel 0.06% (ingenol mebutate)

Snippet

Sponsor: LEO Pharma | Conditions: Actinic Keratosis | Phase 2 | Status: COMPLETED | Results posted: 2018-12-07